750 Corporate Drive
94 articles with Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years
The study of Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg] nasal spray) in pediatric patients aged 6 to under 12 years of age met its primary endpoint, and results were consistent with extensive clinical trial experience with Ryaltris in patients 12 years of age and older
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
3/8/2019Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.
Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that Alessandro Riva, MD, will join its new innovation company as Chief Executive Officer.
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the presentation of a new post hoc analysis of data from a Phase 2a, proof-of-concept study of GBR 830 at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Glenmark Pharmaceuticals, a global innovative pharmaceutical company, today announced results from new analyses of pooled data from clinical studies of Ryaltris
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Ryaltris also known as GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration as a treatment of seasonal allergic rhinitis in patients 12 years and older
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a standalone company based in the United States. The new business will have its own chief executive officer and board of directors.
The new innovation company will house the current innovative pipeline of 8 assets (NBEs & NCEs), which includes 5 clinical and 3 pre-clinical assets; and innovation-related R&D centres, manufacturing infrastructure and technology.
Glenmark's branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA
Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018
Glenmark Pharmaceuticals, a global innovative pharmaceutical company, today announced the presentation of new pharmacokinetic data from the ongoing Phase 1 trial of GBR 1302, a HER2xCD3 bispecific antibody, at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2018 in Geneva, Switzerland
Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris™ at the ACAAI Annual Scientific Meeting 2018
Ryaltris, formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset
Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the decision to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342.
Glenmark Pharmaceuticals Celebrates the Inauguration of its U.S. Manufacturing Site in Monroe, North Carolina
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the official inauguration of its manufacturing site in Monroe, North Carolina.
Glenmark Pharmaceutical will hold an inauguration ceremony of its manufacturing facility built in Monroe, N.C. on Tuesday, October 30, at 10:30 a.m.
Data on Glenmark Pharmaceuticals' GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference
Glenmark Pharmaceuticals will be presented at the Fall Clinical Dermatology Conference in Las Vegas.
Mitra Biotech Announces Partnership with Glenmark Pharmaceuticals to Provide Clinically Relevant Translational Platform Supporting Development of Immuno-Oncology Portfolio
Mitra Biotech today announced a partnership with Glenmark Pharmaceuticals focused on advancing Glenmark's proprietary immuno-oncology drug pipeline.
Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
Exclusive license agreement potentially worth more than $120 million in addition to royalties